-+ 0.00%
-+ 0.00%
-+ 0.00%

Valneva's IXCHIQ Shows 94% Seroresponse Five Years After Single Dose

PUBT·11/13/2026 15:10:15
Listen to the news
Valneva's IXCHIQ Shows 94% Seroresponse Five Years After Single Dose
  • Valneva today reported five-year study results showing sustained antibody responses following a single dose of its chikungunya vaccine IXCHIQ.
  • Older adults showed antibody persistence comparable to younger adults, supporting the vaccine’s potential to provide long-term protection across age groups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-073616), on November 13, 2026, and is solely responsible for the information contained therein.